European Companies Search Engine
EU funding (€7,113,779): Nanomedicine upscaling for early clinical phases of multimodal cancer therapy Hor1 Apr 2016 EU Research and Innovation programme "Horizon"
Overview
Text
Nanomedicine upscaling for early clinical phases of multimodal cancer therapy
This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project. The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer. NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities: • Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process. • Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD). This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).
Funded Companies:
| Company name | Funding amount |
| Biokeralty Research Institute Aie | €1,494,864 |
| Centre National de la Recherche Scientifique CNRS | €0.00 |
| CHEMICELL GmbH | €174,171 |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | €630,634 |
| Fundacion Imdea Nanociencia | €729,697 |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos III | €88,538 |
| Fundacio Privada Institut D'Investigacio Oncologica de Vall-Hebron (Vhio) | €347,979 |
| Hospital Universitario de Fuenlabrada | €553,625 |
| Immupharma plc | €175,250 |
| Resonant Circuits Ltd. | €888,685 |
| The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | €671,040 |
| UNIVERSITATSKLINIKUM JENA | €755,768 |
| Universite Paris Cite | €603,528 |
Source: https://cordis.europa.eu/project/id/685795
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Biokeralty Research Institute Aie - EU funding (€7,113,779): Nanomedicine upscaling for early clinical phases of multimodal cancer therapy"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
